We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000392
First Posted: January 18, 2000
Last Update Posted: February 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institute of Mental Health (NIMH)
Results First Submitted: July 17, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Care Provider);   Primary Purpose: Treatment
Conditions: HIV Infections
Cognition Disorders
Interventions: Drug: Peptide T
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of 457 persons screened for cognitive impairment, 205 men and 10 women were randomized (106 to peptide T and 109 to placebo).

Reporting Groups
  Description
Peptide T

Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months

Peptide T

Placebo

Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months

Placebo


Participant Flow:   Overall Study
    Peptide T   Placebo
STARTED   106   109 
COMPLETED   66 [1]   77 [1] 
NOT COMPLETED   40   32 
[1] provided complete NP outcome data constituted the sample for the primary efficacy analyses



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Peptide T

Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months

Peptide T

Placebo

Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months

Placebo

Total Total of all reporting groups

Baseline Measures
   Peptide T   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 106   109   215 
Age, Customized [1] 
[Units: Participants]
     
18-39 years   60   62   122 
[1] Information is not available for all participants.
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      5   4.7%      5   4.6%      10   4.7% 
Male      101  95.3%      104  95.4%      205  95.3% 
Race/Ethnicity, Customized [1] 
[Units: Participants]
     
White   83   94   177 
Hispanic   16   9   25 
Black   5   5   10 
[1] Information is not available for all participants.
Region of Enrollment 
[Units: Participants]
     
United States   106   109   215 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Global Neurocognitive Performance z Score From Baseline   [ Time Frame: Baseline and 6 months ]

2.  Secondary:   Change in Neurocognitive Performance Domain z Scores From Baseline   [ Time Frame: Baseline and 6 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Benedetto Vitiello, MD - Supervisory Medical Officer
Organization: NIMH
phone: 301-443-3357
e-mail: bvitiell@mail.nih.gov


Publications:

Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00000392     History of Changes
Other Study ID Numbers: N01 MH00013
First Submitted: January 17, 2000
First Posted: January 18, 2000
Results First Submitted: July 17, 2015
Results First Posted: August 4, 2015
Last Update Posted: February 28, 2017